Travaux scientifiques

Doç. Dr. Ezgi Değerli

38 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil
  1. Clinicopathological Predictors of Axillary Pathological Complete Response and Its Prognostic Significance in Clinically Node-Positive (cN+), HER2-Positive Breast Cancer Following Neoadjuvant Therapy

    Medicina, 2026

    DOI 10.3390/medicina62010200 PMID 41597486 Texte intégral en libre accèsSource : OpenAlex

  2. Pathological Response and Survival Outcomes Following Neoadjuvant Chemotherapy in HR+/HER2- Breast Cancer: Real-world Experience

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2026-3-9 Texte intégral en libre accèsSource : OpenAlex

  3. Prognostic Value of BMI in Patients with Metastatic Cervical Cancer:A Retrospective Study From Turkey

    OncoTargets and therapy, 2026

    DOI 10.2147/ott.s622194 PMID 42644128 Texte intégral en libre accèsSource : Europe PMC

  4. Prognostic value of CT-measured baseline tumor volume in nivolumab-treated metastatic renal cell carcinoma

    Tumori, 2026

    DOI 10.1177/03008916261490843 PMID 42847292 Source : Europe PMC

  5. Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy

    Medicina, 2025

    DOI 10.3390/medicina61071168 PMID 40731799 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  6. Clinical Analysis of Multiple Primary Malignant Tumors: A Single-Center Experience

    Cerrahpasa Medical Journal, 2025

    DOI 10.5152/cjm.2025.25022 Texte intégral en libre accèsSource : OpenAlex

  7. Effects of immune related adverse events and corticosteroids on the outcome of patients treated with immune checkpoint inhibitors

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-91102-z PMID 39984593 11 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  8. Docetaxel-induced severe neuropathy, a case of breast cancer with GTSP1 polymorphism

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2025

    DOI 10.1177/10781552241279831 PMID 39195359 Source : Europe PMC

  9. Neutrophil–Lymphocyte Ratio and Prognostic Nutritional Index Predict Prognosis for Definitive Chemoradiotherapy in Cervical Cancer

    Indian Journal of Gynecologic Oncology, 2025

    DOI 10.1007/s40944-025-01029-6 Source : OpenAlex

  10. The Relationship Between Changes in the Neutrophil-Lymphocyte Ratio (NLR) and Radiological Progression in Cervical Cancer

    Istanbul Medical Journal, 2025

    DOI 10.4274/imj.galenos.2025.59254 Texte intégral en libre accèsSource : OpenAlex

  11. The Relationship Between Hemoglobin to Albumin Ratio and Disease-Free Survival in Patients with Locally Advanced Nasopharyngeal Cancer Treated with Chemoradiotherapy

    Bakirkoy Tip Dergisi / Medical Journal of Bakirkoy, 2025

    DOI 10.4274/bmj.galenos.2025.2025.3-8 Texte intégral en libre accèsSource : OpenAlex

  12. Ghrelin Levels and Disease Localization in Inflammatory Bowel Disease: A Correlation Study

    Sakarya Medical Journal, 2025

    DOI 10.31832/smj.1679691 Texte intégral en libre accèsSource : OpenAlex

  13. Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with Immunotherapy

    Medicina, 2024

    DOI 10.3390/medicina60122103 PMID 39768982 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  14. Obesity Is an Independent Prognostic Factor That Reduced Pathological Complete Response in Operable Breast Cancer Patients

    Medicina, 2024

    DOI 10.3390/medicina60121953 PMID 39768835 8 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  15. The impact of HER2-low status on pathological complete response and disease-free survival in early-stage breast cancer

    BMC Cancer, 2024

    DOI 10.1186/s12885-024-13064-1 PMID 39448928 2 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  16. Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors

    Clinical & Translational Oncology, 2024

    DOI 10.1007/s12094-024-03696-x PMID 39225958 3 citations (Europe PMC) Source : OpenAlex

  17. Effect of body mass index on immune checkpoint inhibitor efficacy in patients with advanced cancer

    Tumori Journal, 2024

    DOI 10.1177/03008916241291989 PMID 39506383 Texte intégral en libre accèsSource : OpenAlex

  18. Apelin Levels According to the Site of Involvement in Inflammatory Bowel Diseases

    Experimed, 2024

    DOI 10.26650/experimed.1494644 Texte intégral en libre accèsSource : OpenAlex

  19. Assessment of Oral Capecitabine in Elderly Patients with Stage 2 Colon Cancer: Toxicity, Tolerability, and Survival Outcomes

    Istanbul Medical Journal, 2024

    DOI 10.4274/imj.galenos.2024.64606 Texte intégral en libre accèsSource : OpenAlex

  20. Prognostic factors in Kaposi sarcoma, single centre experience

    The Australasian journal of dermatology, 2024

    DOI 10.1111/ajd.14309 PMID 38760927 1 citation (Europe PMC) Source : Europe PMC

  21. Nivolumab Efficacy and Safety in Cancer Patients with Renal Dysfunction

    Medical Bulletin of Haseki, 2024

    DOI 10.4274/haseki.galenos.2024.9916 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  22. Impact of Tumor Location on the Clinicopathologic and Oncologic Outcomes of Stage 1-3 Colon Cancer

    Eurasian Journal of Medical Investigation, 2024

    DOI 10.14744/ejmi.2024.24868 Source : OpenAlex

  23. Major and minor salivary gland cancers: A multicenter retrospective study

    Head & Neck, 2023

    DOI 10.1002/hed.27376 PMID 37084179 8 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  24. PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study

    Journal of Geriatric Oncology, 2023

    DOI 10.1016/j.jgo.2023.101604 PMID 37683369 10 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  25. 149P HER2-low status and response to neoadjuvant chemotherapy in early breast cancer

    ESMO Open, 2023

    DOI 10.1016/j.esmoop.2023.101488 Texte intégral en libre accèsSource : OpenAlex

  26. Relationship between pathological response and molecular subtypes in locally advanced breast cancer patients receiving neoadjuvant chemotherapy

    Journal of chemotherapy (Florence, Italy), 2023

    DOI 10.1080/1120009x.2022.2043514 PMID 35220928 5 citations (Europe PMC) Texte intégral en libre accèsSource : Europe PMC

  27. Effect of antibiotic treatment on immune checkpoint inhibitors efficacy in patients with advanced non-small cell lung cancer

    Lung Cancer, 2023

    DOI 10.1016/j.lungcan.2023.107347 PMID 37597304 24 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  28. A single center's experience of the extrapulmonary neuroendocrine carcinomas

    Northern clinics of Istanbul, 2022

    DOI 10.14744/nci.2021.47887 PMID 35340315 1 citation (Europe PMC) Texte intégral en libre accèsSource : Europe PMC

  29. Serum Irisin Levels in Newly Diagnosed Type 2 Diabetes Mellitus and Prediabetic Patients

    Selçuk Tıp Dergisi, 2022

    DOI 10.30733/std.2022.01540 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  30. The demographic characteristics, prognosis, and relationship with cancer subtypes of hospitalized COVID‐19 patients with malignancy: A single‐center experience

    Journal of Medical Virology, 2021

    DOI 10.1002/jmv.27123 PMID 34081337 7 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  31. Bevacizumab-induced isolated oculomotor nerve palsy in glioblastoma multiforme.

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021

    DOI 10.1177/10781552211066888 PMID 34878367 1 citation (Europe PMC) Source : ORCID

  32. Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer

    Tumori Journal, 2020

    DOI 10.1177/0300891620953468 PMID 32935638 4 citations (Europe PMC) Source : OpenAlex

  33. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma

    Melanoma Research, 2020

    DOI 10.1097/cmr.0000000000000678 PMID 32898388 7 citations (Europe PMC) Source : OpenAlex

  34. A rare case of cardiac toxicity in a patient with imatinib treatment: Case report

    Journal of Cancer Research and Therapeutics, 2020

    DOI 10.4103/jcrt.jcrt_188_19 PMID 35900559 3 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  35. KANSER HASTALARINDA UYKU KALİTESİNİ ETKİLEYEN FAKTÖRLER

    Namık Kemal Tıp Dergisi, 2020

    DOI 10.37696/nkmj.674879 Texte intégral en libre accèsSource : OpenAlex

  36. Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155220964895 PMID 33040673 Source : OpenAlex

  37. Immune-related adverse events associated with immune-checkpoint inhibitors: A single center experience

    Annals of Oncology, 2019

    DOI 10.1093/annonc/mdz449.007 Texte intégral en libre accèsSource : OpenAlex

  38. Temperament characteristics of bipolar patients on lithium therapy and relationship with lithium treatment response

    European Neuropsychopharmacology, 2016

    DOI 10.1016/s0924-977x(16)31417-1 Source : OpenAlex